This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Oak Street Health Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Oak Street Health's earnings have been declining at an average annual rate of -42.7%, while the Healthcare industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 39.1% per year.

Información clave

-42.7%

Tasa de crecimiento de los beneficios

71.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	8.5%
Tasa de crecimiento de los ingresos	39.1%
Rentabilidad financiera	n/a
Margen neto	-23.6%
Última actualización de beneficios	31 Dec 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Oak Street Health, Inc. (NYSE:OSH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Jan 28

Oak Street Health Grows Revenue But Struggles With Higher Medical Costs

Dec 22

Oak Street Health: Poised For Growth Following RubiconMD Deal

Dec 01

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Oak Street Health. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:OSH Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 22	2,161	-509	507
30 Sep 22	1,977	-515	501
30 Jun 22	1,820	-494	483
31 Mar 22	1,650	-442	446
31 Dec 21	1,430	-409	420
30 Sep 21	1,285	-358	404
30 Jun 21	1,114	-282	369
31 Mar 21	976	-159	310
31 Dec 20	883	-120	249
30 Sep 20	808	-85	190
30 Jun 20	729	-93	151
31 Mar 20	641	-145	138
31 Dec 19	557	-137	122
30 Sep 19	470	-119	123
31 Dec 18	318	-119	76
31 Dec 17	185	-55	33

Ingresos de calidad: OSH is currently unprofitable.

Margen de beneficios creciente: OSH is currently unprofitable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: OSH is unprofitable, and losses have increased over the past 5 years at a rate of 42.7% per year.

Acelerando crecimiento: Unable to compare OSH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: OSH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-8.4%).

Rentabilidad financiera

Alta ROE: OSH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company has been acquired

Oak Street Health Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2022 earnings: EPS misses analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Oak Street Health, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings: EPS misses analyst expectations

Oak Street Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Financial Officer recently sold US$232k worth of stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director recently sold US$274k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

CVS Health Corporation (NYSE:CVS) entered into a definitive agreement to acquire Oak Street Health, Inc. (NYSE:OSH) from Newlight Partners LP, General Atlantic LLC and others for $9.6 billion.

Price target increased by 8.5% to US$35.00

CVS Health Corporation (NYSE:CVS) entered into a definitive agreement to acquire Oak Street Health, Inc. (NYSE:OSH) from Newlight Partners LP, General Atlantic LLC and others for $9.6 billion.

CVS close to acquiring Oak Street Health for $10.5B - WSJ

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

CVS Reportedly Explores an Acquisition of Oak Street Health

Oak Street Health jumps on report of CVS takeover interest

Chief Operating Officer notifies of intention to sell stock

Oak Street Health, Inc. Appoints Deb Edberg as First Chief Wellness Officer

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Oak Street Health, Inc. announced that it has received funding

Oak Street Health pares gain on report about takeover chances

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Oak Street Health, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Oak Street Health Q3 2022 Earnings Preview

Chief Operating Officer notifies of intention to sell stock

Oak Street Health, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Chief Operating Officer notifies of intention to sell stock

Board Member notifies of intention to sell stock

Oak Street Health Launches Nurse Practitioner Fellowship in Adult Primary Care

Oak Street Health downgraded at Goldman Sachs citing cloudy outlook

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Operating Officer recently sold US$258k worth of stock

Oak Street Health, Inc. has completed a Follow-on Equity Offering in the amount of $180.25 million.

Oak Street Health, Inc. has completed a Follow-on Equity Offering in the amount of $180.25 million.

Oak Street Health slips aftermarket on secondary stock offering

Consensus forecasts updated

CEO & Chairman notifies of intention to sell stock

Price target increased to US$31.78

Second quarter 2022 earnings: EPS misses analyst expectations

Oak Street Health, Inc. Provides Earnings Guidance for the Three Months Ending September 30, 2022 and Twelve Months Ending December 31, 2022

Oak Street Health Q2 2022 Earnings Preview

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Oak Street Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Oak Street Health, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2022 and for the Full Year Ending December 31, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Innovation Officer & Director notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Oak Street Health, Inc. to Report Q1, 2022 Results on May 03, 2022

Chief Innovation Officer & Director notifies of intention to sell stock

Full year 2021 earnings: EPS exceeds analyst expectations

Jakubowitz Law Commences Securities Fraud Class Action Lawsuit on Behalf of Shareholders of Oak Street Health, Inc

Oak Street Health, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Oak Street Health, Inc. (NYSE:OSH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Price target decreased to US$46.00

Chief Innovation Officer & Director notifies of intention to sell stock

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Oak Street Health, Inc

Price target decreased to US$50.38

President notifies of intention to sell stock

Chief Innovation Officer & Director notifies of intention to sell stock

Oak Street Health Grows Revenue But Struggles With Higher Medical Costs

COO & Director exercised options to buy US$161k worth of stock.

Desglose de ingresos y gastos
Beta